Quisque scit quod cancer pulmonis, cancer gastricus, cancer intestinalis, et cancer pectoris faciliter ad protegendum per examen physicum, ideo aegros cancer mature dignoscitur bonum deploratum habere et eorum superstes tempus multum protractum est.
However, liver cancer, another serious life-threatening cancer that accounts for more than 55% of the world’s cancers in China, is difficult to be diagnosed early. Most patients are diagnosed late and lose the chance of surgery. Although other treatments are diverse, it is difficult to maintain long-term survival. The early diagnosis of iecoris cancer has always been a difficult problem in the tumor world.
Hoc tempore, victoria scientiarum Sinensium nostra superbia maxime digna est!
Pridie Kalendas Aprilis, Acta Academiae Scientiarum Americanarum (PNAS) cellam liberam DNA (cfDNA) dimisit et interdum venalicium a Centro Nationali Cancri confectum, Hospitalis Cancri Sinensium Academiae Scientiarum Medicarum et Beijing Panshengzi Gene Technologiae Co. ., Ltd. Proventus primorum protegendorum cancri hepatis in cohorte expectationis HBV portantium.
Studium liquidum biopsy methodi cfDNA mutationis genee conjunctae cum notis dapibus independenter a phisicis Sinensium HCCscreen evolvit. Post accuratam verificationem clinicam, investigatio eventus adhibendus expectatur ad primum cancer iecoris tegiendum.
In hoc studio, primo cancer iecoris minus quam 3 cm inveniri potest. Inquisitores periphericum sanguinis exemplaria cella liberorum DNA mutationum et interdum venalicium consecuti sunt, et 331 HBV tabellarios in normalibus alpha-fetoprotein et B-ultrasounds proventuum texerunt.
Proventus 24 casus deprehensi (fortasse cum cancer iecoris), et in sequentibus 6 ad 8 menses, 4 casus inventi sunt cancer iecoris habere. 307 Reliqui aegroti negativi sunt et nullus cancer iecoris per tempus sequens repertum est. C% sensus consequi, 100% proprietatem et 94% valorem positivum predictive.
Early-stage liver cancer can be detected by blood testing from asymptomatic HBV carriers. This technology can achieve accurate detection of common mutations in liver cancer such as cfDNA point mutations, insertion deletion mutations, and HBV virus integration. At present, the research method has been further optimized, the sensitivity is stable at more than 93%, and the specificity can be increased to more than 98%.
Tamen, in praesenti, haec technica adhuc in scaena investigationis est, et nondum publice probata est pro clinico protegendo pro primo iecoris cancer obtegendo. Autem, homines magno periculo vel necessitate pro primo cancro protegendo eligere possunt ad regularem hospitium vel ad examen medicinae pro facultate medici reprehendo-sursum pro primo cancro protegendo!
Hoc tempore multi in Sinis iter et tabernam in Iaponia similes faciunt. Viam medicinae examen perficiendum, inter prima tegimen variarum carcinomatarum, et da tibi tranquillitatem mentis ludentibus, ut corpus sanum curet.
